Trial reportPLoS neglected tropical diseases2021
The entomological impact of passive metofluthrin emanators against indoor Aedes aegypti: A randomized field trial.
Trial report in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Efficacy of volatile pyrethroid spatial repellents to reduce exposure to mosquito and sand fly vectors and human infection risk: a systematic review and meta-analysis.Parasites & vectors · 2026Pooled it
- Systematic review of Aedes aegypti control trials suggests publication bias related to author disclosure of conflicts of interest.PLoS neglected tropical diseases · 2026Pooled it
- Volatile pyrethroid spatial repellents for preventing mosquito bites: a systematic review and meta-analysis.EBioMedicine · 2025Pooled it
- Community deployment of metofluthrin emanators to control indoor Aedes aegypti: Efficacy results from a crossover trial in Yucatan, Mexico.PLoS neglected tropical diseases · 2025Trial
- Mosquito Shield™, a transfluthrin passive emanator, protects against pyrethroid-resistant Anopheles gambiae sensu lato in central Benin.Malaria journal · 2024Trial
- Chemical analysis, repellent, larvicidal, and oviposition deterrent activities of plant essential oils againstFrontiers in insect science · 2025Article
- The effect of novel mosquito bite prevention tools on Anopheles minimus landing and key secondary endpoints: semi-field evaluations in Thailand.Malaria journal · 2024Article
- Review
- Insecticide resistance compromises the control of Aedes aegypti in Bangladesh.Pest management science · 2023Article
- The oral repellent - science fiction or common sense? Insects, vector-borne diseases, failing strategies, and a bold proposition.Tropical diseases, travel medicine and vaccines · 2023Review
- Improving the efficiency of aerosolized insecticide testing against mosquitoes.Scientific reports · 2023Article
- Indoor resting behavior of Aedes aegypti (Diptera: Culicidae) in northeastern Thailand.Parasites & vectors · 2023Article
- Article
- Chemical Composition, Larvicidal and Repellent Activities of Wild Plant Essential Oils againstBiology · 2022Article
- Wolbachia wAlbB inhibit dengue and Zika infection in the mosquito Aedes aegypti with an Australian background.PLoS neglected tropical diseases · 2022Article
- Natural Aedes-Borne Virus Infection Detected in Male Adult Aedes aegypti (Diptera: Culicidae) Collected From Urban Settings in Mérida, Yucatán, México.Journal of medical entomology · 2022Article
- Article
- Effectiveness of Aedes-borne infectious disease control in Latin America and the Caribbean region: A scoping review.PloS one · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundIn the absence of vaccines or drugs, insecticides are the mainstay of Aedes-borne disease control. Their utility is challenged by the slow deployment of resources, poor community compliance and inadequate household coverage. Novel application methods are required. METHODOLOGY AND PRINCIPAL
findingsA 10% w/w metofluthrin "emanator" that passively disseminates insecticide from an impregnated net was evaluated in a randomized trial of 200 houses in Mexico. The devices were introduced at a rate of 1 per room and replaced at 3-week intervals. During each of 7 consecutive deployment cycles, indoor resting mosquitoes were sampled using aspirator collections. Assessments of mosquito landing behaviours were made in a subset of houses. Pre-treatment, there were no differences in Aedes aegypti indices between houses recruited to the control and treatment arms. Immediately after metofluthrin deployment, the entomological indices between the trial arms diverged. Averaged across the trial, there were significant reductions in Abundance Rate Ratios for total Ae. aegypti, female abundance and females that contained blood meals (2.5, 2.4 and 2.3-times fewer mosquitoes respectively; P<0.001). Average efficacy was 60.2% for total adults, 58.3% for females, and 57.2% for blood-fed females. The emanators also reduced mosquito landings by 90% from 12.5 to 1.2 per 10-minute sampling period (P<0.05). Homozygous forms of the pyrethroid resistant kdr alleles V410L, V1016L and F1534C were common in the target mosquito population; found in 39%, 24% and 95% of mosquitoes collected during the trial. CONCLUSIONS/SIGNIFICANCE: This is the first randomized control trial to evaluate the entomological impact of any volatile pyrethroid on urban Ae. aegypti. It demonstrates that volatile pyrethroids can have a sustained impact on Ae. aegypti population densities and human-vector contact indoors. These effects occur despite the presence of pyrethroid-resistant alleles in the target population. Formulations like these may have considerable utility for public health vector control responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.